Visual contrast sensitivity and neuroimaging measures of Alzheimer’s disease pathophysiology

Takeaway

  • Cerebral amyloid and tau deposition is strongly associated with visual contrast sensitivity, as measured by frequency doubling technology (FDT), across the spectrum of Alzheimer’s disease (AD) progression and in specific at-risk groups.

Why this matters

    Current tools that can identify AD biomarkers have limited availability, which restricts their use in widespread clinical practice and research. The findings in this article support the use of visual contrast sensitivity as a new, cost-effective and easily administered biomarker for AD related pathology in older patients at risk of cognitive decline.